Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
VIENNA, Austria, May 18, 2007 – Intercell AG (VSE,“ICLL”) has been informed by its strategic partnerMerck & Co., Inc. on the results of a Phase I study involvingin total over 120 adult healthy volunteers comparing safety andimmunogenicity of different doses of the Staphylococcus aureusvaccine. The Staphylococcus aureus vaccine is based on a conserved prote...Intercell AG: Novel tuberculosis Vaccine Shows Promising Immunogenicity and Safety Profile
The Danish Statens Serum Institut (SSI) and Intercell from a phase I clinicaltrial with a tuberculosis (TB) subunit vaccine The vaccine is produced by SSI and contains Intercell’sadjuvant IC31™...